缺乏对比增强的成人型弥漫性胶质瘤中预测异柠檬酸脱氢酶突变和1p/19q联合缺失的MRI评分系统
该回顾性研究纳入两家三级医院2012年1月至2022年4月病理确诊的、增强MRI无对比增强的成人型弥漫性胶质瘤,开发并验证基于标准临床MRI序列的简单评分系统预测IDH和1p/19q状态。T2-FLAIR不匹配征对IDH突变特异度和阳性预测值均为100%;IDH状态和1p/19q联合缺失预测的内部验证AUC分别为0.86和0.73,外部验证分别为0.99和0.88。
要点
- T2-FLAIR不匹配征对IDH突变的特异度和阳性预测值均为100%。
- 无错配征肿瘤的IDH预测评分系统纳入年龄、ADC比值和形态学特征。
- IDH突变胶质瘤的1p/19q联合缺失预测纳入ADC比值、皮质受累和错配征。
核心结论
- T2-FLAIR不匹配征及使用标准临床MRI的评分系统可预测无对比增强胶质瘤的IDH和1p/19q联合缺失状态。
研究设计与样本
- 回顾性研究纳入两家三级医院2012年1月至2022年4月病理确诊的成人型弥漫性胶质瘤,增强MRI无对比增强;内部验证队列237例(平均年龄44.4岁±14.4[SD],男性136例,IDH预测193例、1p/19q预测163例),外部验证队列35例(46.1岁±15.3,男性20例,IDH预测28例、1p/19q预测24例);采用T2-FLAIR不匹配征、MRI特征视觉评分、ADC比值和相对脑血容量,通过单变量和多变量逻辑回归开发评分系统并进行校准和区分度评估(含内部和外部验证)。
关键影像表现/征象
- T2-FLAIR不匹配征对IDH突变显示100%特异度和100%阳性预测值。
- 无错配征肿瘤的IDH状态预测评分系统纳入年龄、ADC比值和形态学特征。
- IDH突变胶质瘤的1p/19q联合缺失预测纳入ADC比值、皮质受累和错配征。
诊断标准与关键数值
- T2-FLAIR不匹配征预测IDH突变:特异度100%,阳性预测值100%。
- IDH状态预测评分系统(用于无错配征肿瘤):纳入年龄、ADC比值和形态学特征。
- 1p/19q联合缺失预测(用于IDH突变胶质瘤):纳入ADC比值、皮质受累和错配征。
- IDH状态预测的内部验证bootstrap校正AUC为0.86(95%CI:0.81,0.90),外部验证AUC为0.99(95%CI:0.98,1.0)。
- 1p/19q联合缺失预测的内部验证bootstrap校正AUC为0.73(95%CI:0.65,0.81),外部验证AUC为0.88(95%CI:0.63,1.0)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background According to 2021 World Health Organization criteria, adult-type diffuse gliomas include glioblastoma, isocitrate dehydrogenase (IDH)-wildtype; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and astrocytoma, IDH-mutant, even when contrast enhancement is lacking. Purpose To develop and validate simple scoring systems for predicting IDH and subsequent 1p/19q codeletion status in gliomas without contrast enhancement using standard clinical MRI sequences. Materials and Methods This retrospective study included adult-type diffuse gliomas lacking contrast at contrast-enhanced MRI from two tertiary referral hospitals between January 2012 and April 2022 with diagnoses confirmed at pathology. IDH status was predicted primarily by using T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign, followed by 1p/19q codeletion prediction. A visual rating of MRI features, apparent diffusion coefficient (ADC) ratio, and relative cerebral blood volume was measured. Scoring systems were developed through univariable and multivariable logistic regressions and underwent calibration and discrimination, including internal and external validation. Results For the internal validation cohort, 237 patients were included (mean age, 44.4 years ± 14.4 [SD]; 136 male patients; 193 patients in IDH prediction and 163 patients in 1p/19q prediction). For the external validation cohort, 35 patients were included (46.1 years ± 15.3; 20 male patients; 28 patients in IDH prediction and 24 patients in 1p/19q prediction). The T2-FLAIR mismatch sign demonstrated 100% specificity and 100% positive predictive value for IDH mutation. IDH status prediction scoring system for tumors without mismatch sign included age, ADC ratio, and morphologic characteristics, whereas 1p/19q codeletion prediction for IDH-mutant gliomas included ADC ratio, cortical involvement, and mismatch sign. For IDH status and 1p/19q codeletion prediction, bootstrap-corrected areas under the receiver operating characteristic curve were 0.86 (95% CI: 0.81, 0.90) and 0.73 (95% CI: 0.65, 0.81), respectively, whereas at external validation they were 0.99 (95% CI: 0.98, 1.0) and 0.88 (95% CI: 0.63, 1.0). Conclusion The T2-FLAIR mismatch sign and scoring systems using standard clinical MRI predicted IDH and 1p/19q codeletion status in gliomas lacking contrast enhancement. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Badve and Hodges in this issue.
引用
- Kang KM, Song J, Choi Y, et al. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement. Radiology. 2024. PMID: 38713025. doi:10.1148/radiol.233120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。